Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03689010 · ClinicalTrials.gov registry record · Phase 1
To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea
A Phase 1 study, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 1
- Development phase
- 1,116
- Enrollment target
NCT03689010 is a Phase 1 study that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 1,116 participants.
The verdict
NCT03689010, a Phase 1 study, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1,116 participants
- Enrollment target
Study Summary
To demonstrate the superiority of the efficacy of the test and reference products over that of the placebo control in the treatment of moderate facial rosacea.
Interventions
- DRUG Azelaic acid foam 15%
- DRUG Finacea® (Azelaic acid Foam) 15%
- DRUG Vehicle of the test product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,116 participants |
| Start Date | 2017-12-12 |
| Est. Completion | 2018-09-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03689010
The ClinicalTrials.gov registry entry for NCT03689010 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 1,116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Azelaic acid foam 15% is the first listed.
NCT03689010 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03689010 about?
NCT03689010 is a clinical study titled "To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea". To demonstrate the superiority of the efficacy of the test and reference products over that of the placebo control in the treatment of moderate facial rosacea.
What is the current status of trial NCT03689010?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1,116 participants. The study started on 2017-12-12. Estimated completion is 2018-09-28.
What interventions are being tested in trial NCT03689010?
The interventions under investigation include: Azelaic acid foam 15% (DRUG), Finacea® (Azelaic acid Foam) 15% (DRUG), Vehicle of the test product (DRUG).
Who is sponsoring clinical trial NCT03689010?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.